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Abstract
Background: Coronary artery bypass grafting (CABG) is often used to treat patients with significant coronary heart 
disease (CHD). To date, multiple longitudinal and cross-sectional studies have examined the association between 
depression and CABG outcomes. Although this relationship is well established, the mechanism underlying this 
relationship remains unclear. The purpose of this study was twofold. First, we compared three markers of autonomic 
nervous system (ANS) function in four groups of patients: 1) Patients with coronary heart disease and depression (CHD/
Dep), 2) Patients without CHD but with depression (NonCHD/Dep), 3) Patients with CHD but without depression (CHD/
NonDep), and 4) Patients without CHD and depression (NonCHD/NonDep). Second, we investigated the impact of 
depression and autonomic nervous system activity on CABG outcomes.
Methods: Patients were screened to determine whether they met some of the study's inclusion or exclusion criteria. 
ANS function (i.e., heart rate, heart rate variability, and plasma norepinephrine levels) were measured. Chi-square and 
one-way analysis of variance were performed to evaluate group differences across demographic, medical variables, 
and indicators of ANS function. Logistic regression and multiple regression analyses were used to assess impact of 
depression and autonomic nervous system activity on CABG outcomes.
Results: The results of the study provide some support to suggest that depressed patients with CHD have greater ANS 
dysregulation compared to those with only CHD or depression. Furthermore, independent predictors of in-hospital 
length of stay and non-routine discharge included having a diagnosis of depression and CHD, elevated heart rate, and 
low heart rate variability.
Conclusions: The current study presents evidence to support the hypothesis that ANS dysregulation might be one of 
the underlying mechanisms that links depression to cardiovascular CABG surgery outcomes. Thus, future studies 
should focus on developing and testing interventions that targets modifying ANS dysregulation, which may lead to 
improved patient outcomes.
Background
It is estimated that 16 million American adults have coro-
nary heart disease (CHD). CHD remains the leading
cause of death in the United States with 652,091 regis-
tered deaths in 2005 [1]. To date, multiple longitudinal
and cross-sectional studies have examined the associa-
tion of CHD with psychological functioning, particularly
depression [2,3]. Over 100 studies have investigated this
relationship, thus providing evidence that depression is
prevalent (18% to 60%) in patients with CHD. This
comorbidity has significant adverse effects on the course
and outcome of CHD [4-7]. Depressed patients are twice
as likely as nondepressed patients to have a major cardiac
event within 12 months of the diagnosis of coronary
artery disease [8]. In addition, the risk of mortality is
greater in depressed patients compared to nondepressed
after the following events: CHD [4], acute myocardial
i n f a r c t i o n  [ 9 ] ,  a n  e p i s o d e  o f  u n s t a b l e  a n g i n a  [ 1 0 ] ,  o r
CABG [4,5].
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Although the relationship between depression and car-
diac events is well established, the mechanism underlying
this relationship remains unclear [11]. However, three
lines of evidence suggest that altered autonomic nervous
system (ANS) activity in depressed patients might be
responsible for the increased risk of mortality and medi-
cal morbidities in patients with CHD. First line of evi-
dence originates from early reports of ANS dysregulation
in depression was found in studies of medically ill
patients with major depressive disorder (MDD). These
studies found elevated levels of plasma and urinary cate-
cholamines, primarily norepinephrine (NE), in depressed
patients compared with controls [12-14]. These findings
are significant because the concentrations of plasma NE
generally parallel the level of activity of the sympathetic
nervous system (SNS) and are highly correlated with
sympathetic neural activity [14].
A second line of evidence is based on the consistent
f i n d i n g s  t h a t  r e s t i n g  H e a r t  R a t e  ( H R )  i s  h i g h e r  i n
depressed than nondepressed patients [14-16]. Depres-
sion is also associated with exaggerated HR response to
physical and psychological stressors in both medically
well individuals [17] as well as in patients with CHD [18].
As regulation of HR occurs primarily through a recipro-
cal interaction of the sympathetic and parasympathetic
nervous system, and given that one of the functions of
ANS is to regulate HR, elevated HR suggests dysregula-
tion of cardiac ANS function.
A third line of evidence is based on studies reporting
decreased Heart Rate Variability (HRV) among depressed
patients compared to nondepressed controls [8,19,20].
Over the last two decades, HRV has emerged as an
important marker for examining the continuous interplay
between the parasympathetic and sympathetic influences
on HR that yields information about autonomic flexibility
[21]. Increased HRV has been used as a marker of
increased vagal activity and has been consistently associ-
ated with greater capacities to regulate stress, emotional
arousal, and attention [22] while low HRV has been asso-
ciated with excessive cardiac sympathetic modulation,
inadequate parasympathetic modulation, or both [23]. A
number of studies have found HRV to be lower in
depressed psychiatric patients compared to controls
[20,21]. There is even greater evidence that HRV is lower
in depressed than nondepressed patients with CHD
[24,25].
In summary, there is considerable evidence of auto-
nomic cardiovascular dysregulation in depressed patients
as well as in patients with CHD. However, it is unknown
whether patients with CHD and depression have greater
ANS dysregulation relative to patients with either depres-
sion or CHD alone (i.e., comorbidity versus single mor-
bidity). It is also unknown whether ANS dysregulation
explains the increased morbidity and mortality in
patients with both disorders. Thus, the purpose of this
study was twofold. First, we compared three markers of
ANS function in four groups of patients: 1) Patients with
coronary heart disease and depression (CHD/DEP), 2)
Patients without CHD but with depression (NonCHD/
Dep), 3) Patients with CHD but without depression
(CHD/NonDep), and 4) Patients without CHD and
depression (NonCHD/NonDep). Second, we investi-
g a t e d  t h e  a s s o c i a t i o n  o f  A N S  a c t i v i t y  ( H R ,  H R V ,  a n d
plasma NE levels) impact of depression and autonomic
nervous system activity on CABG outcomes.
Second, we investigated the association between these
markers of ANS function and group classification in car-
diac patients (i.e., CHD/DEP vs. CHD/NonDep) and
CABG outcomes (i.e., in-hospital length of stay and
patient's type of discharge (i.e., routine or nonroutine),
while holding constant potential differences in medical
(e.g., diabetes, history of myocardial infarction, etc.) and
sociodemographic (e.g., age, gender, etc.) variables. We
hypothesized that patients in the CHD/Dep group will
have the greatest dysregulation in autonomic function
while patients in the NonCHD/NonDep group will have
the least amount of autonomic dysregulation compared
to the other 2 groups. We also hypothesized that ANS
markers and group classification in cardiac patients will
significantly predict in-hospital length of stay and
patient's type of discharge. Specifically, there will be a sig-
nificant positive association between HR and plasma NE
levels and in-hospital length of stay. There will be a signif-
icant negative association between HRV and in-hospital
length stay. In addition, patients in the CHD/Dep group
will more likely be discharged non-routinely discharged
following a CABG operation than those with CHD only.
Both of these hypotheses reflect a possible additive effect
of depression and heart disease on ANS dysregulation.
Methods
Participants
A sample of patients was recruited from private sector
hospitals in the Northeast to form four groups of
patients: 1) Patients with CHD and depression (CHD/
DEP), 2) Patients without CHD and with depression
(NonCHD/Dep), 3) Patients with CHD and without
depression (CHD/NonDep), and 4) Patients without
CHD and depression (NonCHD/NonDep). It should be
noted that patients without depression have no current
major depressive episodes. Patients with a history of
depression, or minor forms of depression may be
included in the nondepressed group.
Procedure
Patients in the CHD/Dep and CHD/NonDep groups
were recruited from patients who have a CHD diagnosis
and were scheduled to undergo a first-time CABG withDao et al. Journal of Cardiothoracic Surgery 2010, 5:36
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or without concomitant valve procedure. Patients in the
NonCHD/NonDep group were recruited from a primary
care clinic within the hospital while patients in the Non-
CHD/Dep group were recruited from the hospital's out-
patient mental health clinics. Those who consented to
participate in the study were assessed to determine if they
met the study eligibility criteria. The inclusion criteria for
the CHD/Dep group consisted of being enrolled to
undergo a CABG operation, and having a diagnosis of
MDD. The exclusion criteria for the CHD/DEP group
were significant cognitive deficits or other psychiatric
diagnoses. The inclusion criterion for the CHD/NonDep
group consisted of being enrolled to undergo a CABG
operation. The exclusion criteria for the CHD/NonDep
group consisted of significant cognitive deficits, a diagno-
sis of MDD, or any other psychiatric diagnosis. The inclu-
sion criterion for the NonCHD/Dep group consisted of a
diagnosis of MDD. The exclusion criteria for this group
consisted of a diagnosis CHD, significant cognitive defi-
cits, or any other psychiatric diagnosis. Patients in the
NonCHD/NonDep group were excluded if they had a
diagnosis of MDD, CHD, significant cognitive deficits, or
any other psychiatric diagnosis.
Screening
Patients were initially screened to determine whether
they met inclusion or exclusion criteria. Psychiatric inter-
view and a psychophysiological assessment were con-
ducted on all subjects who consented to participate in the
study.
Psychiatric Interview
The MINI International Neuropsychiatric Interview
(MINI) [26] is a standardized diagnostic instrument for
the diagnosis of psychiatric disorders using the Diagnos-
tic and Statistical Manual, 4th edition (DSM-IV-TR) [27]
and International Classification of Diseases (ICD) - 10
psychiatric disorders [28]. It consists of standardized,
structured, closed-end questions throughout its diagnos-
tic procedure The MINI has demonstrated adequate reli-
ability and validity. Inter-rater and test-retest reliabilities
were high among the majority of disorders. Validities
with other lengthy structured diagnostic interviews such
as the Structured Clinical Interview (SCID) for DSM-IIIR
h a v e  bee n  r e po rt ed  [ 2 6 ] .  R es ea r c h  h as  s h o wn  t h a t  t h e
MINI can be used successfully as a gold standard of psy-
chiatric diagnosis in multi-center clinical trials and epide-
miology studies [29]. The MINI was used to make the
diagnosis of MDD.
Heart Rate and Heart Rate Variability Measurement
After a 12 hour fast which includes abstinence from
smoking and a seated rest of 30 minutes, the HR, HRV
and plasma NE levels were measured for each subject.
The assessment of HR and HRV were gathered via
recordings of EKG and respiration using the Nexus 10
BioTrace equipment and associated software version
1.16. The Nexus 10 is a 10 channel physiological monitor-
ing and feedback platform that offers data acquisition at
up to 2048 samples per second. It is a certified class 2-1
(EU) medical device. Following previous conventions
[30], patients were excluded from further analysis if they
were not in predominantly regular sinus rhythm or if they
had sustained atrial arrhythmias such as atrial fibrillation
o r  g r e a t e r  t h a n  1 0 %  e c t o p i c  c o m p l e x e s .  D u r i n g  E K G
measurement, participants were instructed to maintain
open eyes and avoid moving their wrists while the experi-
menter read excerpts from a collection of pleasant travel
stories. This is a common HRV experimental paradigm
designed to mimic normal waking state levels of arousal
[31]. HRV was recorded for 15 minutes for each partici-
pant. At the end of the session the recordings were coded
and saved for subsequent analysis. Movement artifacts
above a certain threshold were automatically removed
from the session overview which provides a display of the
total session of respiration and heart rate data. Following
previous convention [32], heart rate data were averaged
across 60 seconds intervals at a sampling rate of 512 hertz
and edited by averaging premature ectopic beats that
exceeded a 25% difference between two consecutive data
points. HRV was calculated as the standard deviation of
all normal-to-normal RR intervals (SDNN; intervals
between adjacent QRS complexes).
Plasma Norepinephrine Assessment
Blood samples (1.2 mL) were drawn from the antecubital
vein by acute venipuncture and were contained in chilled,
heparinized tubes containing ethylene glycol tetraacetic
acid and 200 mmol/L reduced gluthione. The plasma was
then stored in polystyrene tubes at −70°C until assayed.
The assay and laboratory procedures for measuring NE
have been described in detail elsewhere [33], and have
been used by other investigators in similar studies [34].
Medical Covariates
A number of plausible variables has been identified that
could influence ANS regulation, particularly HR, HRV,
and plasma NE levels. To help partition out the effects of
these variables, we have included the following covari-
ates: age, education, race, diabetes mellitus, hypertension,
history of asthma, history of myocardial infarction, ciga-
rette smoking, alcohol consumption, level of physical
activity, body mass index (BMI), and the Deyo score [35].
The Deyo Score is a comorbidity index that was
adapted from the Charlson Comorbidity Index [36]. It is
designed to capture comorbid conditions recorded in the
inpatient setting using ICD-9-CM diagnosis and proce-
dure codes and has been widely used in outcomes studies
with administrative datasets as the principal dataDao et al. Journal of Cardiothoracic Surgery 2010, 5:36
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source[37]. The Deyo Score assesses comorbid medical
conditions such as myocardial infarction, congestive
heart failure, peripheral vascular disease, cerebrovascular
disease, dementia, chronic obstructive pulmonary dis-
ease, rheumatologic disease, mild liver disease, diabetes
melllitus, diabetic complications, hemiplegia or paraple-
gia, renal disease, malignancy, moderate to severe liver
disease, metastatic solid tumors, and acquired immune
deficiency syndrome/human immunodeficiency viral
infection. The Deyo Score was determined by weighted
scoring of comorbidities. Individual comorbidities were
then combined to form a Deyo Score [35].
Patients were considered smokers if they smoked1 pack
or more of cigarettes per week and for at least 5 years
were considered smokers. BMI was assessed using a BMI
calculator that took into consideration the patient's
weight and height. Physical activity was assessed using
the International Physical Activity Questionnaires
(IPAQ) [38]. The IPAQ consists of eight items that esti-
mate the time spent performing physical activities (low to
high). A number of studies have been conducted on the
IPAQ, showing that it produces reliable data as well as
acceptable concurrent, criterion, and construct validity
[38,39].
Alcohol consumption was measured using the Alcohol
Use Disorders Identification Test (AUDIT) [40]. The
AUDIT is a 10-item self-report questionnaire. Each of the
questions has a set of responses to choose from, and each
response has a score ranging from 0-4. All the responses
were then added to form a total score. A recent system-
atic review of the literature has concluded that the
AUDIT is the best screening instrument for the range of
alcohol problems in primary care [41].
Outcome Variables
Outcome variables in this study included length of inpa-
tient hospital stay and patient disposition. Length of inpa-
tient hospital stay (measured in days) is defined as the
difference between the hospital admission date and the
date of discharge for the patient. Disposition of patients
was coded as routine or non-routine. Patients were coded
as having a non-routine disposition if they were dis-
charged to short-term hospital, skilled nursing facility,
intermediate care facility, another type of facility, home
health care, or against medical advice.
Statistical Analysis
We hypothesized that patients in the CHD/Dep group
will have the greatest dysregulation in autonomic func-
tion while patients in the NonCHD/NonDep group will
have the least amount of autonomic dysregulation com-
pared to the other 2 groups. To examine our first hypoth-
esis, chi-square and one-way analysis of variance
(ANOVA) were performed to evaluate group differences
across demographic and medical variables, as well as
markers of ANS dsyregulation. Any variables that dif-
fered significantly between the four groups were used in
subsequent regression models as covariates to assess the
independent impact of ANS indicators on medical out-
comes following CABG. Our second hypothesis was that
ANS markers and group classification of cardiac patients
(see above) will significantly predict in-hospital length of
stay and patient discharge disposition. Specifically, there
will be a significant positive association between HR and
plasma NE levels and in-hospital length of stay. There will
be a significant negative association between HRV and
in-hospital length stay. In addition, patients that are in
the CHD/Dep group will more likely be discharged non-
routinely following a CABG operation than those in the
CHD/NonDep group. To address these hypotheses, logis-
tic regression and multiple regression analyses were used.
Logistic regression analysis was conducted with patient
discharge disposition as an outcome variable after con-
trolling for the effects of age, Deyo score, physical activ-
ity, and BMI (i.e., variables that were significant in
previous chi-square and ANOVA analyses). Independent
variables in this analysis include group membership, HR
and HRV. Multivariable regression analysis was also per-
formed assessing the impact of group membership, HR,
and HRV on in-hospital length of stay after controlling
for the effects of age, Deyo score, physical activity, and
BMI.
Results
Chi square test and separate one-way ANOVAs were
conducted to evaluate the relationship between groups of
patients and demographic and medical characteristics
(See Table 1). The independent variable had four levels:
CHD/Dep, CHD/NonDep, NonCHD/Dep, andNon-
CHD/NonDep. The dependent variables were demo-
graphic, medical, and ANS dysregulation variables. For
age, the ANOVA was significant, F(3, 358) = 3.75, p =
.011. The strength of the relationship between groups of
patients and age, as assessed by η2, was weak, with the
groups of patient factor accounting for 1% of the variance
of the dependent variable. For the Deyo score, the
ANOVA was significant, F(3, 358) = 5.59, p = .001. The
strength of the relationship between groups of patients
and the Deyo score was weak with the groups of patient
factor accounting for 4.5% of the variance of the depen-
dent variable. For BMI, the ANOVA was significant, F(3,
358) = 7.46, p < .001. The strength of the relationship
between groups of patients and the BMI was weak with
the groups of patient factor accounting for 5.9% of the
variance of the dependent variable. The four groups also
differ on physical activity, χ2 (3, n = 362) = 45.6, p < .05
(two-tailed), with ϕ = .067. For heart rate, the ANOVA
was significant, F(3, 358) = 13.3, p < .001. The strength ofDao et al. Journal of Cardiothoracic Surgery 2010, 5:36
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Table 1: Demographic and Medical Characteristics
Characteristics CHD/Dep (1) NonCHD/Dep (2) CHD/NonDep (3) NonCHD/NonDep (4) p Post Hoc
Age 61.3
(8.3)
59.2
(9.1)
62.0
(9.3)
58.3
(7.5)
.011 3 > 4*
Education 10.3
(4.9)
12.1
(6.3)
12.2
(7.1)
11.9
(6.6)
.169
Race .326
Caucasian 81.9%
(68)
79.3%
(73)
81.4%
(79)
91.2%
(82)
African American 9.6%
(8)
14.2%
(13)
10.3%
(10)
6.6%
(6)
Hispanic 8.5%
(7)
6.5%
(6)
8.3%
(8)
2.2%
(2)
Deyo score 1.39
(1.04)
.961
(1.35)
1.30
(.933)
.776
(1.23)
.001 1 > 4*
3 > 4*
History of MI 34.9%
(29)
35.9%
(33)
35.1%
(34)
20%
(18)
.062
History of asthma 3.6%
(3)
5.4%
(5)
7.2%
(7)
4.4%
(4)
.724
Cigarette Smoker 55.4%
(46)
59.7%
(55)
57.3%
(56)
42.2%
(38)
.054
AUDIT 25.8
(6.2)
27.4
(7.2)
26.4
(5.8)
19.6
(4.3)
Physical Activity .003
Low 63.9% (53) 62.0%
(57)
51.5%
(50)
35.6%
(32)
Moderate 26.5%
(22)
33.7%
(31)
37.1%
(36)
50.0%
(45)
High 9.6%
(8)
4.3%
(4)
11.3%
(11)
14.4%
(13)
Diabetes 26.5%
(22)
25%
(23)
28.9%
(28)
13.3%
(12)
.064
Hypertension 32.5%
(27)
28.2%
(26)
30.9%
(30)
16.7%
(15)
.073
Body mass index (BMI) 29.7
(7.2)
29.3
(6.4)
27.8
(8.8)
24.9
(8.2)
< .001 1 > 4*
2 > 4*
Heart rate 76.3
(11.4)
74.4
(12.2)
71.4
(10.9)
66.9
(10.3)
< .001 1 > 3 > 4*
2 > 4*
Heart rate variabilitya 19.79
(7.9)
24.53
(7.6)
24.89
(7.88)
50.51
(12.5)
< .001 1 < 2 < 4*
1 < 3 < 4*
Plasma NEb 293
(99)
343
(175)
308
(211)
341
(160)
.120
Note. AUDIT = Alcohol Use Disorders Identification Test. CHD/Dep = Patients with CHD and depression. NonCHD/Dep = Patients without CHD 
but with depression. CHD/NonDep = Patients with CHD but without depression. NonCHD/NonDep = Patients without CHD or depression. 
aStandard deviation of RR (msec). balog transformed pg/ml. * p < .05.
the relationship between groups of patients and HR was
weak, with the groups of patient factor accounting for
16% of the variance of the dependent variable. For HRV,
the ANOVA was significant, F(3, 358) = 205.1, p < .001.
The strength of the relationship between groups of
patients and HR was strong, with the groups of patient
factor accounting for 46% of the variance of the depen-
dent variable.
Follow-up tests were conducted to evaluate the pair-
wise differences among the means. Because the variancesDao et al. Journal of Cardiothoracic Surgery 2010, 5:36
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among the four groups ranged from 55.5 to 85.7, we
chose not to assume the variances were homogeneous
and conducted post hoc comparisons with the use of the
Dunnett's C test, a test that does not assume equal vari-
ances among the four groups. For age, there was a signifi-
cant difference in the means between the CHD/NonDep
and the NonCHD/NonDep groups with the CHD/Non-
Dep group being older than the NonCHD/NonDep
group. For the Deyo score, there were significant differ-
ences in the means between the CHD/Dep and Non-
CHD/NonDep groups and the CHD/NonDep and the
NonCHD/NonDep groups with the CHD/DEP and the
CHD/NonDep groups having higher means scores on the
Deyo score compared to the NonCHD/NonDep group.
For the BMI, there were significant differences in the
means between the CHD/Dep+Dep+CHD and Non-
CHD/NonDep groups and between the NonCHD/Dep
and the NonCHD/NonDep groups with the CHD/DEP
and the NonCHD/Dep groups having higher means
scores on the BMI compared to the NonCHD/NonDep
group. For heart rate, the CHD/DEP group had the high-
est HR followed by the CHD/NonDep and the NonCHD/
NonDep groups. For HRV, the CHD/Dep group had the
lowest HRV while the NonCHD/NonDep group had the
highest HRV.
Table 2 contains results of logistic regression analysis
with patient discharge disposition (non-routine = 1 and
routine = 0) as an outcome variable after controlling for
the effects of age, Deyo score, physical activity, and BMI.
Independent significant predictors of patient discharge
were the following: being in the CHD/Dep group (OR:
1.43, HR (OR: 1.39), and HRV (OR: .597). Table 3 con-
tains results of multivariable regression analysis with
length of in-hospital stay as the dependent variable. The
adjusted R2 of .26 indicates that a fourth of the variability
in length of stay is predicted by group, HR, and HR vari-
ability. Independent significant predictors included:
group classification (B = 1.56), HR (B = .058), and HRV (B
= .-963).
Discussion
Despite the significant contribution in the literature on
mental health and cardiovascular diseases, we simply do
not know at this time which mechanisms account for the
relationship between depression and outcomes following
a CABG surgery [11]. Also, to the best of our knowledge,
there are no published studies that compared the inci-
dence of ANS dysregulation in patients with both CHD
and depression, to those with either depression or CHD
alone. It is also unknown whether ANS dysregulation
could explain CABG outcomes. These two questions are
important to address because if ANS dysregulation is
what links depression CABG outcomes, then recognition
and treatment of ANS dysregulation may lead to
improved patient outcomes. Thus, it was in this frame-
work that we sought to address ANS dysregulation and
outcomes following a CABG operation.
Our initial analyses revealed that age, Deyo score, phys-
ical activity, BMI, HR, and HRV were significantly differ-
ent across the four groups. Specifically, patients that had
CHD only were significantly older than the patients who
did not have CHD or depression. Also, those that had
CHD with or without depression have higher Deyo scores
than patients who did not have CHD or depression. This
is expected given that the Deyo score reflects 17 comor-
bid medical conditions.
The measurement of ANS regulation/dysregulation has
long been debated in the medical community. In our
study, we defined ANS dysregulation as having a high
basal HR, low HRV, and high plasma NE levels. Based on
this definition, we found that patients with both depres-
sion and heart disease have the greatest autonomic dys-
regulation compared to the other three groups. The
results supported our first hypothesis showing that
patients diagnosed with both CHD and depression have
HR and lower HRV than patients in the other three
groups. However, the findings were not consistent for
plasma NE levels; this unexpected finding might be due
to the following reasons: It is well documented that there
are many factors that can influence plasma levels of cate-
Table 2: Logistic Regression Analysis Predicting Routine Discharge after controlling for the Effects of Age, Deyo score, 
Physical Activity, and BMI (n = 180)
Variable B SE B Wald's Statistic Odds Ratio (95% CI)
Group (1 = CHD/DEP, 0 = CHD/NonDep) .516* .023 14.3 1.43 (1.33-2.63)
Heart rate .343* .121 15.5 1.12 (1.02-1.04)
Heart rate variability -.513** .094 19.9 .597 (.497-.718)
Note. CHD/DEP = coronary artery disease (CHD) and depression. - CHD/NonDep = CHD but without depression. * p < .05. ** p < .01.Dao et al. Journal of Cardiothoracic Surgery 2010, 5:36
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cholamines such as psychological stress, temperature,
posture, exercise, medications, and food intake [42]. Fur-
thermore, the sympathetic nervous system consists of
many different nerves that are distributed throughout the
body. Consequently, the measurement of sympathetic
nerve activity in one area of the body may not truly
reflect sympathetic nerve activity throughout the body.
Moreover, we collected blood samples from the antecu-
bital vein. Given that sympathetic nerve activity in the
arm may influence levelsof antecubital plasma NE levels,
this measurement of plasma NE level may not accurately
reflect plasma NE levels throughout the body . As sug-
gested by others [43,44], total body sympathetic nerve
activity might be better assessed using arterialized
venous sampling and plasma NE kinetic techniques that
r e l y  o n  d i l u t i o n  o f  r a d i o l a b e l e d  N E  a n d  m a t h e m a t i c a l
modeling to provide estimates of postganglionic norepi-
nephrine release and clearance.
The results supported our initial hypothesis that there
are group differences across indicators of ANS activity.
However, group differences do not provide much support
that ANS dsyregulation predicts outcome following a
CABG operation. Thus, in our subsequent research ques-
tions we examined whether markers of ANS activity pre-
dicted in-hospital length of stay and patient discharge
disposition. It was found that there was increased length
of stay and greater likelihood of having a non-routine dis-
charge following CABG in patients with both depression
and CHD compared to those with CHD only. This finding
is interesting for the following reasons. First, it suggests
that HR and HRV may have an additive effect to CABG
outcomes. Second, by including group classification as an
independent variable in our analyses (and after control-
ling for potential confounding variables), we were able to
assess whether there was an association between group
classification and outcomes following a CABG operation.
Despite the positive findings, there are several limita-
tions to consider, the first of which involves extraneous
variables that might inflate the systematic error in the
study. Despite statistically controlling for a number of
extraneous variables to remove some of the variability in
the dependent variable that is due to these extraneous
variables, there were other variables that were not con-
trolled for during the study. Because of the nature of the
study, which limits the ability to randomly assign patients
to different conditions, variables such as the number of
grafts patients received and medications that they were
currently taking might have a systematic effect on (corre-
lates with) length of stay and patient discharge disposi-
tion. Secondly, although this study used the MINI in
diagnosing patients, it did not assess reliability of diagno-
ses using multiple raters. Thirdly, the generalizability of
the results of this study to the general population is lim-
ited because the study had only male patients and it
included patients with depression but without comorbid
psychiatric disorders. And Finnaly, the index that was
used in t his  s t udy was S DNN .  S DNN is  a n ac c epta ble
measure of HRV for short term measurements. There
have been studies of short term HRV as predictors of car-
diac mortality and morbidity. However, most studies of
HRV and depression in CHD has calculated HRV from 24
hour ambulatory monitoring and used frequency domain
indices of HRV.
Conclusions
In summary, the current study presents evidence to sup-
port the hypothesis that ANS dysregulation might be one
of the underlying mechanisms that links depression to
CABG outcomes. However, further research is needed to
control for other potential covariates such as diet and
testing conditions to confirm that ANS dysregulation is
the mechanism underlying these two conditions. Also,
these preliminary results suggest that we begin to focus
on treatment-related questions. For instance, future stud-
ies should focus on developing and testing interventions
that targets modifying ANS dysregulation. Furthermore,
it would be beneficial to know if improved ANS regula-
tion can decrease morbidity and mortality in depressed
CHD patients following CABG. This line of research may
guide therapeutics especially that HRV can be modified
through pharmacologic and biobehavioral therapies as
well as exercise and exercise therapies [45].
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